National Consensus on Non-metastatic Castration-Resistant Prostate Cancer: more than just a snapshot
AUTOR(ES)
Reis, Leonardo Oliveira; Col, Luciana Saboya Brito Dal; Sadi, Marcus Vinícius
FONTE
Int. braz j urol.
DATA DE PUBLICAÇÃO
2021-03
RESUMO
ABSTRACT Introduction: The rapid spread of coronavirus disease 2019 (COVID-19) has dramatic effects on individuals and health care systems. In our institute, a tertiary oncologic public hospital with high surgical volume, we prioritize maintaining cancer treatment as well as possible. The aim of this study is to evaluate if uro-oncological surgeries at pandemic are safe. Materials and Methods: We evaluated patients who underwent uro-oncological procedures. Epidemiological data, information on COVID-19 infection related to surgery and clinical characteristics of non-survival operative patients with COVID-19 infections were analyzed. Results: From 213 patients analyzed, Covid-19 symptoms were noticed in 8 patients at preoperative process or at hospital admission postponing operation; 161 patients were submitted to elective surgery and 44 to emergency surgery. From patients submitted to elective surgeries, we had 1 patient with laboratory confirmation of COVID-19 (0,6%), with mild symptoms and quick discharge. From the urgencies group, we had 6(13%) patients tested positive; 5 were taken to ICU with 4 deaths. Conclusion: Elective uro-oncological procedures at the COVID-19 epidemic period in a COVID-19-free Institute are safe, and patients who need urgent procedures, with a long period of hospitalization, need special care to avoid COVID-19 infection and its outcomes.
Documentos Relacionados
- Castration-resistant prostate cancer: systemic therapy in 2012
- Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223
- Phase I Study of Samarium-153 Lexidronam With Docetaxel in Castration-Resistant Metastatic Prostate Cancer
- Editorial Comment: Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223
- Patients' preferences for the management of non-metastatic prostate cancer: discrete choice experiment